O13: Oral infigratinib for children with achondroplasia: Month 18 results from the PROPEL 2 study - Ravi Savarirayan; Elena Muslimova; Josep Bergua; Paul Arundel; Jean Salles; Vrinda Saraff; Borja Delgado; Antonio Leiva-Gea; Helen McDevitt; Marc Nicolino; Massimiliano Rossi; Maria Salcedo; et al. (Genetics in Medicine Open)